Eli Lilly Expands into Autoimmune Sector with $2.875B Merida Biosciences Acquisition

Pharmaceutical titan Eli Lilly (NYSE: LLY) has unveiled a significant deal, agreeing to acquire biotech startup Merida Biosciences for a staggering $2.875 billion in cash. This move allows the Indianapolis-based drugmaker to strategically reinvest the profits from its successful obesity drug portfolio into new therapeutic sectors.

Unlike Lilly’s flagship weight-loss drugs, Mounjaro and Zepbound — which reported a combined revenue increase of 73% year-over-year, reaching nearly $14.9 billion in Q2 2026, Merida is focusing on a different disease category. The biotech is pioneering a new class of biologics aimed at selectively degrading pathogenic autoantibodies that trigger immune-mediated diseases, without extensively suppressing the immune system. Its leading program, MER511, is currently undergoing Phase 1 testing for Graves’ disease and thyroid eye disease.

The acquisition, expected to be finalized in Q4 2026 subject to regulatory approvals, aligns with CEO David Ricks’ declared goal to invest in technologies that can emulate the transformative influence Lilly has had on obesity medicine in other disease areas. This acquisition marks Lilly’s latest move in an active 2026 M&A spree that has already surpassed $25 billion across 10 transactions — accounting for more than half of all M&A spending by the top 12 pharma companies this year.

Source: CNBC – August 31, 2026